Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Selecting Dividend Aristocrats Using SCHD Methodology - Mounting A Comeback
11:02am, Tuesday, 28'th Mar 2023
I propose leveraging the stock selection criteria from the underlying index of SCHD to build a portfolio with a subset of Dividend Aristocrats. I am tracking two portfolios built using this process an
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
10:20am, Tuesday, 28'th Mar 2023 Zacks Investment Research
Sector ETF report for FHLC
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
10:15am, Tuesday, 28'th Mar 2023
Milvexian is a drug candidate under development by Bristol Myers and Johnson & Johnson. In a phase 2 clinical trial, milvexian produced encouraging results in preventing strokes.
It's a Mistake to Ignore the Growth Potential of These 3 Dividend Stocks
09:10am, Tuesday, 28'th Mar 2023 The Motley Fool
Coca-Cola, J&J, and IBM are still solid long-term income investments.
It's a Mistake to Ignore the Growth Potential of These 3 Dividend Stocks
05:10am, Tuesday, 28'th Mar 2023
Coca-Cola's well-diversified portfolio of beverages creates an evergreen play. Johnson & Johnson's mix of pharmaceuticals, medical devices, and consumer products makes it a good stock in bear and bull
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
09:45pm, Monday, 27'th Mar 2023 Zacks Investment Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $153.30, marking a +0.43% move from the previous day.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
01:00pm, Monday, 27'th Mar 2023 Zacks Investment Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:43am, Monday, 27'th Mar 2023
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
10:20am, Monday, 27'th Mar 2023 Zacks Investment Research
Smart Beta ETF report for DGRW
Better Buy: AbbVie vs. Johnson & Johnson
09:30am, Saturday, 25'th Mar 2023 The Motley Fool
These pharma giants beat the bear market last year.
Better Buy: AbbVie vs. Johnson & Johnson
05:30am, Saturday, 25'th Mar 2023
AbbVie and J&J both are facing big transitions this year. These stocks look inexpensive today, both trading at around 14 times forward earnings estimates.
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
12:33pm, Friday, 24'th Mar 2023
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
10:20am, Friday, 24'th Mar 2023 Zacks Investment Research
Smart Beta ETF report for DGRO
Have $1,000? 2 Smart Stocks to Buy This Month
02:15pm, Thursday, 23'rd Mar 2023 The Motley Fool
The market is still giving investors great opportunities to buy exceptional companies.
My Top 10 Dividend Growth Stocks For March 2023
02:00pm, Thursday, 23'rd Mar 2023
In today's article, I will present 10 dividend growth companies that I currently consider to be particularly attractive. The 10 selected picks have shown an Average Dividend Growth Rate of 12.92% over
